MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 5,000 shares of the company's stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $4.41, for a total value of $22,050.00. Following the completion of the sale, the director now owns 120,583 shares of the company's stock, valued at approximately $531,771.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
John Joseph Johnston also recently made the following trade(s):
- On Friday, January 26th, John Joseph Johnston sold 5,000 shares of MaxCyte stock. The stock was sold at an average price of $5.12, for a total transaction of $25,600.00.
MaxCyte Trading Down 3.0 %
NASDAQ MXCT opened at $4.19 on Friday. MaxCyte, Inc. has a 1 year low of $2.45 and a 1 year high of $5.55. The company has a market cap of $436.17 million, a PE ratio of -11.32 and a beta of 1.36. The stock's 50-day moving average price is $4.64 and its two-hundred day moving average price is $4.20.
Analysts Set New Price Targets
MXCT has been the topic of several recent research reports. William Blair reaffirmed an "outperform" rating on shares of MaxCyte in a research note on Wednesday, March 13th. BTIG Research reduced their target price on shares of MaxCyte from $10.00 to $8.00 and set a "buy" rating for the company in a report on Wednesday, March 13th. Finally, Stephens reaffirmed an "overweight" rating and issued a $11.00 price target on shares of MaxCyte in a report on Wednesday, March 13th.
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
From Banyan Hill Publishing | Ad
If you think AI is big, then you have got to check out something I call Imperium…
By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Watch my video for all of the details
Read Our Latest Report on MaxCyte
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Quantbot Technologies LP purchased a new stake in shares of MaxCyte in the 2nd quarter valued at approximately $27,000. PNC Financial Services Group Inc. purchased a new stake in shares of MaxCyte in the fourth quarter valued at $29,000. Victory Capital Management Inc. acquired a new stake in shares of MaxCyte in the third quarter worth $31,000. Johnson Investment Counsel Inc. purchased a new position in shares of MaxCyte during the third quarter valued at $34,000. Finally, Tower Research Capital LLC TRC raised its position in MaxCyte by 139.8% during the first quarter. Tower Research Capital LLC TRC now owns 7,108 shares of the company's stock valued at $35,000 after buying an additional 4,144 shares during the period. 68.81% of the stock is owned by hedge funds and other institutional investors.
MaxCyte Company Profile
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
